<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/Newsletter/style.css"/>
<title>Quest Diagnostics (DGX): Assessing Valuation Following Launch of Nationwide Pharmacogenomic Test for Precision Medicine â€” Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/Newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Quest Diagnostics (DGX): Assessing Valuation Following Launch of Nationwide Pharmacogenomic Test for Precision Medicine</h2>
    <div class="badge">2025-09-08T14:14:29+00:00</div>
    <ul>
      <li>Result: Fair Value of $188.19 (UNDERVALUED) Have a read of the narrative in full and understand what&#x27;s behind the forecasts.</li>
<li>Most Popular Narrative: 2.5% Undervalued The most followed narrative sees Quest Diagnostics trading below its estimated fair value, with analysts projecting modest upside from current levels.</li>
<li>This announcement arrives at a moment when Quest Diagnostics is already showing positive stock momentum, with shares returning 21% over the past year and nearly matching that gain year-to-date.</li>
<li>It offers actionable guidance that could make prescribing both safer and more effective.</li>
<li>This supports long-term earnings power.</li>
<li>Curious about why experts think there is still room for this stock to climb?</li>
<li>Want to discover the underlying numbers and key assumptions driving this price target?</li>
    </ul>
    <p>
      <a class="btn" href="https://x.com/intent/tweet?text=Quest%20Diagnostics%20%28DGX%29%3A%20Assessing%20Valuation%20Following%20Launch%20of%20Nationwide%20Pharmacogenomic%20Test%20for%20Precision%20Medicine%0A%E2%80%A2%20Result%3A%20Fair%20Value%20of%20%24188.19%20%28UNDERVALUED%29%20Have%20a%20read%20of%20the%20narrative%20in%20full%20and%20understand%20what%27s%20behind%20the%20forecasts.%0A%E2%80%A2%20Most%20Popular%20Narrative%3A%202.5%25%20Undervalued%20The%20most%20followed%20narrative%20sees%20Quest%20Diagnostics%20trading%20below%20its%20estimated%20fair%20value%2C%20with%20analysts%20projecting%20modest%20upside%20from%20current%20levels.%0A%E2%80%A2%20This%20announcement%20arrives%20at%20a%20moment%20when%20Quest%20Diagnostics%20is%20already%20showing%20positive%20stock%20momentum%2C%20with%20shares%20returning%2021%25%20over%20the%20past%20year%20and%20nearly%20matching%20that%20gain%20year-to-date.%0A%E2%80%A2%20It%20offers%20actionable%20guidance%20that%20could%20make%20prescribing%20both%20safer%20and%20more%20effective.%0A%E2%80%A2%20This%20supports%20long-term%20earnings%20power.%0A%E2%80%A2%20Curious%20about%20why%20experts%20think%20there%20is%20still%20room%20for%20this%20stock%20to%20climb%3F%0A%E2%80%A2%20Want%20to%20discover%20the%20underlying%20numbers%20and%20key%20assumptions%20driving%20this%20price%20target%3F&url=https%3A%2F%2Fsuavir600.github.io%2FNewsletter%2Farticles%2Fquest-diagnostics-dgx-assessing-valuation-following-launch-of-nationwide-pharmac%2F" target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a class="btn" href="https://finance.yahoo.com/news/quest-diagnostics-dgx-assessing-valuation-141429190.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>